ArticleFrontiers in physiology2022
Fixed Airflow Obstruction in Asthma: A Problem of the Whole Lung Not of Just the Airways.
Article in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Lung function improvement following smoking cessation in chronic respiratory conditions: A meta-analytic approach.The Journal of international medical research · 2025Pooled it
- Lung Function-Based Assessment of Small Airway Dysfunction in Chronic Respiratory Diseases.Biology · 2026Review
- A data-driven approach to stock inhaler programming implementation in Chicago Public Schools.Discover public health · 2026Article
- The importance of mechanical forces in chronic respiratory diseases.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Early benefit of mepolizumab on small airways in severe asthma: insights from the IMPOSE study.ERJ open research · 2025Article
- Krebs von den Lungen-6 (KL-6) as a diagnostic and prognostic biomarker for non-neoplastic lung diseases.Clinical chemistry and laboratory medicine · 2025Article
- The Impact of Age and Disease Entity on Small Airway Dysfunction in Obstructive Airway Diseases.International journal of chronic obstructive pulmonary disease · 2025Article
- Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction.ERJ open research · 2024Article
- Effect of fluticasone propionate/formoterol and fluticasone furoate/vilanterol on adolescents with chronic bronchial obstruction.The journal of allergy and clinical immunology. Global · 2024Article
- Respiratory symptoms, exacerbations and sleep disturbances are more common among participants with asthma and chronic airflow limitation: an epidemiological study in Estonia, Iceland and Sweden.BMJ open respiratory research · 2024Article
- Staphylococcal Enterotoxin-Specific IgE Sensitization: A Potential Predictor of Fixed Airflow Obstruction in Elderly Asthma.Allergy, asthma & immunology research · 2023Article
- Asthma and Fixed Airways Obstruction: Real Life Aspects.Advances in respiratory medicine · 2023Article
- Quantitative CT Metrics for the Prediction of Therapeutic Effect in Asthma.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma with irreversible or fixed airflow obstruction (FAO) is a severe clinical phenotype that is difficult to treat and is associated with an accelerated decline in lung function and excess morbidity. There are no current treatments to reverse or prevent this excessive decline in lung function in these patients, due to a lack of understanding of the underlying pathophysiology. The current paradigm is that FAO in asthma is due to airway remodeling driven by chronic inflammation. However, emerging evidence indicates significant and critical structural and functional changes to the lung parenchyma and its lung elastic properties in asthma with FAO, suggesting that FAO is a 'whole lung' problem and not just of the airways. In this Perspective we draw upon what is known thus far on the pathophysiological mechanisms contributing to FAO in asthma, and focus on recent advances and future directions. We propose the view that structural and functional changes in parenchymal tissue, are just as (if not more) important than airway remodeling in causing persistent lung function decline in asthma. We believe this paradigm of FAO should be considered when developing novel treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.